The best outcome for involved parties is a settlement; Amarin “winning” the appeal, while possible, is still a coin flip at best odds are 50:50. Generics are in a lose, lose bigger scenario....if generics “win” appeals they still can’t launch free of legal risks in US. If generics lose appeal, H&R have lost all negotiable leverage and will leave the party without a gift bag...just the bill.